SCHEMBL1620719

SCHEMBL1620719

C/C=C/c1nc2c(N3CCOCC3)nc(SCc3ccc(OC)cc3)nc2n1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
NPSR1 Q6W5P4 3/20 0.51
PDE10A Q9Y233 1/20 0.43
TSHR P16473 2/20 0.42
HPGD P15428 2/20 0.42
HSD17B10 Q99714 1/20 0.42
LMNA P02545 4/20 0.40
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PIK3CD O00329 1/20 0.40
PIK3R1 P27986 1/20 0.40
DCTPP1 Q9H773 1/20 0.40
PIK3CA P42336 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL98753 1.00 ALDH1A1 (0.51) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98754 1.00 ALDH1A1 (0.51) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL99966 0.87 ALDH1A1 (0.54) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98635 0.85 ALDH1A1 (0.52) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL97423 0.83 ALDH1A1 (0.51) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98381 0.81 ALDH1A1 (0.54) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98731 0.80 ALDH1A1 (0.47) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98691 0.79 PDE10A (0.55) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98561 0.79 ALDH1A1 (0.50) ALDH1A1NPSR1PDE10ATSHRHPGD
SCHEMBL98340 0.78 PIK3CA (0.47) ALDH1A1NPSR1PDE10APIK3CDPIK3R1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
US-9132130-B2 Purine derivative and antitumor agent using same ZENYAKU KOGYO KABUSHIKI KAISHA (JP) 2015-09-15 US disclosed
EP-2426130-B1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KK (JP) 2015-03-11 EP disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME ZENYAKU KOGYO KABUSHIKIKAISHA (JP) 2012-04-12 US disclosed
WO-2010126101-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME 全薬工業株式会社 (JP) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120088765-A1 PURINE DERIVATIVE AND ANTITUMOR AGENT USING SAME PNP, TYMP, DPYD ALDH1A1 336/4885NPSR1 2537/4885PDE10A 775/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.